Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model
about
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)Doxorubicin-induced carbonylation and degradation of cardiac myosin binding protein C promote cardiotoxicityTeaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolismSystemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant TempolMitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications.Determination of protein carbonyls in plasma, cell extracts, tissue homogenates, isolated proteins: Focus on sample preparation and derivatization conditions.Antiproliferative effects of mitochondria-targeted cationic antioxidants and analogs: Role of mitochondrial bioenergetics and energy-sensing mechanismTherapeutic Targeting of the Mitochondria Initiates Excessive Superoxide Production and Mitochondrial Depolarization Causing Decreased mtDNA IntegrityDrug-induced mitochondrial dysfunction and cardiotoxicity.Carfilzomib reverses pulmonary arterial hypertension.Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.Mitochondrial potassium channels as pharmacological target for cardioprotective drugs.Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies.Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction.Aspalathin Reverts Doxorubicin-Induced Cardiotoxicity through Increased Autophagy and Decreased Expression of p53/mTOR/p62 Signaling.Nitroxides as Antioxidants and Anticancer Drugs.Mitochondrial dysfunction activates lysosomal-dependent mitophagy selectively in cancer cells.Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to Doxorubicin in tumor-bearing spontaneously hypertensive rats.Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats.
P2860
Q22676705-B3F623A7-48B1-4207-A85B-2A901A821ACAQ28306329-53E11458-3EA7-47CA-B151-209D9580DF81Q33607463-635DCC27-1DAF-47A4-AD33-E6D75DFC01C5Q34202564-4C21FC53-22F2-45E1-84FB-851FADF1A903Q34203187-4D4E7C38-CC88-4517-8D36-6A54628251AAQ35148462-2162434B-164F-49E1-9D61-76E5C88D3472Q35682608-26B5DDE3-99C3-4704-A383-3D29530FFCA8Q35767081-2A354136-63D5-4B87-B835-B96BC22101E5Q36234714-C11AAFD8-6E44-4E8D-8111-51B9BE68E71BQ36339445-9DE166A9-A7A9-40F6-BFF4-5807A2CB8B0EQ36812649-3581226C-1065-4B1F-AB6E-40A548696968Q37613120-017E340B-FDB7-4DB7-9534-E23C5EB618B4Q38262884-B81B4A16-0A17-4FDD-9E0B-D5A8BE34C475Q38692444-D7B74F5C-13FC-4783-9517-6868D743E737Q39264180-6384A5AD-3456-47C5-B22B-CEC16832C6B7Q39400621-4651007A-8322-444D-AC50-51D636F9FBC7Q40982094-C74365F7-95D0-487C-8BE7-C07EE80DBDE9Q46309786-B09A61F7-A260-4D27-9E64-7E0B0109C7DAQ47121511-119A86DE-A3B5-4852-AE07-03CB32DF51D9Q49304282-87914893-511E-4AD5-BDB6-3457C2140E93Q51012946-EA65C345-A016-4B9A-9457-1C5CFC73CE26Q55409914-5A12189B-3EDA-4A99-B4CF-2BC80A4E2588
P2860
Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@ast
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@en
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@nl
type
label
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@ast
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@en
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@nl
prefLabel
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@ast
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@en
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@nl
P2093
P2860
P1433
P1476
Mito-tempol and dexrazoxane ex ...... breast tumor preclinical model
@en
P2093
Asako J Nakamura
Baikuntha Aryal
Balaraman Kalyanaraman
Christophe E Redon
Elliot Rosen
Emily Shacter
Eugene Herman
Gang Cheng
Jennifer S Dickey
Joy Joseph
P2860
P304
P356
10.1371/JOURNAL.PONE.0070575
P407
P577
2013-01-01T00:00:00Z